Navigation Links
Palomar Medical Technologies to Host Fourth Quarter and Year End 2008 Financial Results Conference Call and Webcast on February 5, 2009
Date:1/29/2009

BURLINGTON, Mass., Jan. 29 /PRNewswire-FirstCall/ -- Palomar Medical Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, will hold its quarterly conference call of its 2008 fourth quarter and year end financial results on Thursday, February 5, 2009 at 11:30AM Eastern Time. If you would like to participate, please call (800) 597-0339 at 11:20 AM Eastern Time on that day. The telephone replay will be available one hour after the call at (888) 286-8010 passcode 52026952 and continue through Thursday, February 19, 2009.

A live webcast of Palomar's conference call will be available in the Investor Relations' section of the Company's web site www.palomarmedical.com . Institutional investors can access the call via Thomson Financial's password-protected event management site, StreetEvents (www.streetevents.com). The online archive will be available one hour after the call and continue through Thursday, February 19, 2009.

For more information on Palomar and its products, visit Palomar's website at www.palomarmedical.com . To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations' section of the website.

About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has granted The Procter & Gamble Company a non-exclusive License Agreement to certain patents, technology and FDA documents related to the home-use, light-based hair removal field for women. In addition, Palomar has an exclusive development and license agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.


    Contact: Kayla Castle
             Investor Relations Manager
             Palomar Medical Technologies, Inc.
             781-993-2411
             ir@palomarmedical.com

'/>"/>
SOURCE Palomar Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reliant Technologies, and Palomar Medical Technologies, Announce Launch of a Fractional Technology Licensing Program
2. Palomar Medical Technologies and Reliant Technologies Announce Launch of a Fractional Technology Licensing Program
3. Palomar Medical Reports Financial Results for Third Quarter 2008
4. Palomar Medical Technologies to Host Second Quarter 2008 Financial Results Conference Call and Webcast on July 31, 2008
5. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
6. Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology
7. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
8. Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms
9. Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast
10. AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages
11. Environmental Tectonics Corporations BioMedical Division Announces Additional Sales of Hyperbaric Monoplace Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... ... institution’s inaugural K-20 Education Summit to be held March 23-25, 2017 in Tampa, ... Jan. 25, 2017. , The keynote speakers include Dr. Michelle R. Weise, executive ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and ... the benefits of making new water infrastructure a number one priority. “As we usher ... expect water infrastructure to become a top priority of our new political change agents.” ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... has earned organic certification under the USDA National Organic Program (NOP) for its ... process, we have established organic production and handling systems to complement our current ...
(Date:1/23/2017)... ... January 23, 2017 , ... “The Inn at the Mill”: a story of love and ... quest to become happy and content. , “The Inn at the Mill” is the ... in Germany and Vermont and is now living in Berks County on Crow Hill. ...
(Date:1/23/2017)... ... ... a time when many people celebrate romance and love by giving cards, candy, flowers or ... present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day special: Spend $100 ... $50 free. , “A lot of people just buy the more predictable gift of ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... -- The global  anxiety disorders and depression treatment market  is expected ... of depression worldwide is anticipated to drive the market growth in the coming ... for antidepressants in the recent years. Continue Reading ... ... ...
(Date:1/23/2017)... , Jan 23, 2017 NeuroVive Pharmaceutical ... has signed a preclinical collaboration agreement with the Children,s Hospital ... J. Falk , M.D., a US key opinion leader in ... ... will evaluate compounds from NeuroVive,s research program, NVP015, in certain ...
(Date:1/21/2017)... Research and Markets has announced the ... Type of Test (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type ... (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), Forecast to 2022" report ... ... market segments, especially clinical lab testing, which has evolved as ...
Breaking Medicine Technology: